Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, placebo controlled registrational Phase 3 trial of RECCE 327 as a topical gel (R327G) for the treatment of diabetic foot infections (DFI)

Next Previous
Trial Profile

A double blind, placebo controlled registrational Phase 3 trial of RECCE 327 as a topical gel (R327G) for the treatment of diabetic foot infections (DFI)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RECCE 327 (Primary)
  • Indications Bacterial infections; Diabetic foot ulcer; Skin infections
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 10 Apr 2025 According to a Recce Pharmaceuticals media release, the company has procured a capital raising of up to approximately A$15.8 million, which will be used to fund this study.
  • 19 Dec 2024 According to a Recce Pharmaceuticals media release, company received Human Research Ethics Committee approval to commence dosing for registrational Phase 3 trial of R327G in patients with diabetic foot infections. Approval from Indonesia national agency of food and drug control Badan Pengawas Obat dan Makanan (BPOM) is imminently expected.
  • 19 Dec 2024 According to a Recce Pharmaceuticals media release, phase 3 read-out and regulatory submission expected in late 2025, with potential approval and commercial launch in H1 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top